What is the 13F Pro Quality Score for TCRT?

13F Pro ranks Alaunos Therapeutics, Inc. (TCRT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TCRT's current score at https://13fpro.ai/research/TCRT (free sign-up required for the full ranking).

Which hedge funds own the most TCRT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TCRT include GEODE CAPITAL MANAGEMENT,, BlackRock,, VANGUARD FIDUCIARY CO. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TCRT as soon as new 13F filings post.

Where does 13F Pro source TCRT data?

All Alaunos Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Alaunos Therapeutics, Inc. files with the SEC under CIK 1107421. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TCRT in?

Alaunos Therapeutics, Inc. (TCRT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TCRT research updated on 13F Pro?

TCRT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Alaunos Therapeutics, Inc.(TCRT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1107421 TCRT stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $15.9M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

TCRT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Alaunos Therapeutics, Inc. (TCRT), a Healthcare sector company. TCRT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $15.9m in revenue. Based on the latest XBRL financial filings (Q1 2026), Alaunos Therapeutics, Inc. reports net income of $-1.0M, free cash flow of $-1.0M. Top institutional holders of TCRT by reported 13-F value include GEODE CAPITAL MANAGEMENT,, BlackRock,, VANGUARD FIDUCIARY CO, based on the most recent SEC filings. TCRT trades on the Nasdaq exchange and files with the SEC under CIK 1107421. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TCRT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alaunos Therapeutics, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-1.0M

Free Cash Flow

Q1 2026

$-1.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-50.0% YoY

$5.0KFY 2025

FY21 $398.0KFY23 $5.0KFY24 $10.0KFY25 $5.0K

Net Income

+10.8% YoY

$-4.2MFY 2025

FY21 $-78.8MFY23 $-4.7MFY24 $-4.7MFY25 $-4.2M

Operating Income

+12.2% YoY

$-4.2MFY 2025

FY21 $-77.5MFY23 $-34.3MFY24 $-4.8MFY25 $-4.2M

EPS (Diluted)

+24.7% YoY

$-2.20FY 2025

FY21 $-0.00FY23 $-2.20FY24 $-2.92FY25 $-2.20

Total Assets

+7.7% YoY

$3.0MFY 2025

FY21 $94.9MFY23 $8.3MFY24 $2.8MFY25 $3.0M

Total Debt

—FY 2025

FY21 $24.1MFY23 $0.00FY24 $0.00FY25 —

Op. Cash Flow

+42.3% YoY

$-2.9MFY 2025

FY21 $-61.5MFY23 $-30.1MFY24 $-5.0MFY25 $-2.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019
Revenue	$5.0K -50.0%	$10.0K +100.0%	$5.0K -98.7%	$398.0K	$0.00	—
Net Income	$-4.2M +10.8%	$-4.7M +0.0%	$-4.7M +94.1%	$-78.8M +1.5%	$-80.0M +32.1%	$-117.8M
Operating Income	$-4.2M +12.2%	$-4.8M +86.0%	$-34.3M +55.8%	$-77.5M +3.5%	$-80.4M -38.9%	$-57.9M
EPS (Diluted)	$-2.20 +24.7%	$-2.92 -32.9%	$-2.20 -87780.0%	$-0.00 +0.0%	$-0.00 +46.8%	$-0.00
Total Assets	$3.0M +7.7%	$2.8M -66.7%	$8.3M -91.3%	$94.9M -35.2%	$146.3M +34.1%	$109.1M
Total Debt	—	$0.00	$0.00 -100.0%	$24.1M	$0.00	—
Operating Cash Flow	$-2.9M +42.3%	$-5.0M +83.5%	$-30.1M +51.0%	$-61.5M -7.8%	$-57.0M -39.6%	$-40.9M

AI Insight: TCRT Financial Trends

Pre-revenue biotech burning ~$1M quarterly with equity eroding toward zero; no commercial progress or funding visibility.

• Zero revenue across all eight quarters; operating and net losses consistent at $1M per quarter.

• Equity oscillating between $1M–$4M; declined from $4M (Q2 2024) to $1M (Q1 2026), signaling ongoing cash depletion.

• Operating cash outflow stable at $1M–$2M quarterly; no pipeline advancement or milestone announcements evident.

⚠ Equity approaching single-digit millions; risk of insolvency or dilutive financing within next 1–2 quarters absent capital raise.

⚠ No debt recorded; balance sheet entirely dependent on remaining equity cushion and external funding access.

AI Insight: TCRT Ratio Trends

Alaunos remains deeply unprofitable with ROE deteriorating to -165.9% in Q4 2025, signaling ongoing cash burn and equity erosion.

• ROE worsened from -114.8% in Q2 2025 to -165.9% in Q4 2025, indicating accelerating shareholder value destruction.

• D/E remained at 0.00 in Q4 2024; no leverage evident, but persistent losses erode equity base.

⚠ ROE volatility—swinging -114.8% to -165.9% quarter-to-quarter—suggests uneven burn or one-time charges masking operational trends.

⚠ ROA declined to -88.8% in Q2 2025; no recovery visible by Q3–Q4 2025. Cash runway critical.

Get alerted when TCRT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Alaunos Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TCRT

GEODE CAPITAL MANAGEMENT, LLC
$64.5K22,560 sh
BlackRock, Inc.
$61.1K21,353 sh
VANGUARD FIDUCIARY TRUST CO
$44.3K15,497 sh
VANGUARD CAPITAL MANAGEMENT LLC
$40.2K14,063 sh
TWO SIGMA INVESTMENTS, LP
$31.0K10,839 sh
CITADEL ADVISORS LLC
$30.1K10,519 sh
XTX Topco Ltd
$29.1K10,174 sh
UBS Group AG
$6.5K2,274 sh
OSAIC HOLDINGS, INC.
$5.1K1,779 sh
Tower Research Capital LLC (TRC)
$4.5K1,583 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$64.5K	22,560
BlackRock, Inc.	$61.1K	21,353
VANGUARD FIDUCIARY TRUST CO	$44.3K	15,497
VANGUARD CAPITAL MANAGEMENT LLC	$40.2K	14,063
TWO SIGMA INVESTMENTS, LP	$31.0K	10,839
CITADEL ADVISORS LLC	$30.1K	10,519
XTX Topco Ltd	$29.1K	10,174
UBS Group AG	$6.5K	2,274
OSAIC HOLDINGS, INC.	$5.1K	1,779
Tower Research Capital LLC (TRC)	$4.5K	1,583

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TCRT on your watchlist

Track score changes the day Alaunos Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TCRT a good stock to buy?

13F Pro's AI-powered analysis of Alaunos Therapeutics, Inc. (TCRT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TCRT are available on the TCRT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TCRT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TCRT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Alaunos Therapeutics, Inc.'s investment landscape.